NEW YORK – The maker of Wegovy filed a federal lawsuit against Eli Lilly on Monday, accusing its largest rival in the obesity drug market of running misleading advertisements that denigrate semaglutide, the active ingredient in Novo Nordisk’s blockbuster weight-loss injections.
The complaint invokes the Lanham Act, the primary federal statute governing false advertising claims. Novo Nordisk alleges that marketing materials for Zepbound, Eli Lilly’s competing glucagon-like peptide-1 receptor agonist, contain claims that are misleading or unsupported by clinical evidence when used to compare the two drugs directly.
The lawsuit arrives at a bruising moment in the commercial rivalry between two companies that together dominate a GLP-1 market analysts project will exceed $100 billion in annual sales by decade’s end. Wegovy generated roughly $7 billion in revenue for Novo Nordisk last year, while Zepbound, approved in November 2023, has rapidly captured market share and outpaced Wegovy in new prescription growth for several consecutive quarters, according to IQVIA dispensing data cited by Wall Street analysts.
Executives at Novo Nordisk declined to specify which marketing claims are at issue, citing active litigation. Lilly did not immediately respond to a request for comment Monday. The company has consistently maintained that Zepbound, which contains tirzepatide, is clinically differentiated from semaglutide-based drugs like Wegovy and Ozempic.
Clinical trial data has shown Zepbound achieving greater average weight loss than Wegovy in certain head-to-head studies, though direct comparison trials with weight loss as a primary endpoint remain limited. That gap in the evidence base is likely to become central to the complaint, which appears to target comparative advertising, a category of promotion in which one company invokes a competitor’s product to assert superiority.
Comparative ads are legal in the United States but must meet strict accuracy standards under the Lanham Act. A plaintiff must show not only that a claim is false or misleading, but that it caused or is likely to cause actual commercial harm. Courts have sometimes been skeptical of false-advertising theories in prescription drug markets, where physicians typically serve as intermediaries between promotional materials and prescribing decisions.
The commercial pressure driving Novo Nordisk’s decision to sue is not difficult to trace. Despite Wegovy’s earlier market entry, Zepbound has outpaced Novo’s product in new prescription growth in recent quarters. Novo Nordisk’s stock has underperformed Lilly’s through much of the past year, partly reflecting investor concern that tirzepatide’s clinical profile gives Lilly a durable competitive edge.
The rivalry has taken on added significance because of Medicare coverage dynamics. The GLP-1 drug access program for Medicare seniors, designed to help patients obtain Wegovy and Zepbound at reduced cost while full Part D coverage is phased in, has made pricing and formulary positioning the primary competitive arena. With fewer levers to differentiate on access, the battle has shifted increasingly to messaging, which is the terrain Novo Nordisk is now taking to court.
Meanwhile, the rapid expansion of GLP-1 prescriptions has brought collateral consequences. Reports of misuse and poisoning incidents linked to compounded semaglutide and tirzepatide have led to scrutiny of how these drugs are dispensed outside formal pharmaceutical supply chains, a concern separate from the lawsuit but shaping the regulatory environment both companies navigate.
Novo Nordisk is also managing a pipeline transition. The company has been advancing oral semaglutide formulations, including Rybelsus for diabetes and a higher-dose obesity pill currently in late-stage clinical trials. Analysts view those oral alternatives as a potential differentiator against Lilly’s injected tirzepatide and the company’s own oral GLP-1 pipeline.
Lanham Act suits between pharmaceutical rivals often carry a distinct strategic calculus. A plaintiff that wins an injunction can force a competitor’s marketing department to rebuild its campaigns, a disruption potentially worth months of market momentum. Recovering damages requires proving that lost sales were directly attributable to the misleading ads, a notoriously difficult standard in markets where multiple variables influence prescribing behavior.
What Novo Nordisk appears to want, at minimum, is a modification of Lilly’s marketing language, achievable through a court order or through a settlement requiring Lilly to amend specific campaigns. Whether that can be accomplished without a full trial will depend on the strength of the specific claims at issue and Lilly’s appetite for protracted litigation.
This is the first known legal action between the two GLP-1 market leaders over promotional content. Any ruling could effectively set guardrails on how the entire class of anti-obesity drugs is marketed, with commercial stakes that extend well beyond either company’s immediate courtroom strategy.
